fda warns semaglutide Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients FDA Gives Ozempic New Side

Nausea is among the most commonly reported adverse events in Phase 2 trial data, occurring most frequently during dose escalation and at higher doses

The goal is maximizing efficacy while maintaining tolerability

References Lau DCW, Erichsen L, Francisco AM, et al

Hims & Hers Healths stock is surging after the telehealth company announced it would introduce affordable compounded GLP-1 weight-loss medications

Conversion chart for 2.5 mg/mL concentration At 2.5 mg/mL, every 1 unit on your insulin syringe equals 0.025 mg of semaglutide

When it comes time to reorder or when a colleague asks for a vendor recommendation, documented evaluations save time and improve decision quality